Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Ageing Research Reviews, ISSN: 1568-1637, Vol: 12, Issue: 1, Page: 116-140
2013
- 36Citations
- 134Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations36
- Citation Indexes36
- 36
- CrossRef29
- Captures134
- Readers134
- 134
Review Description
Alzheimer's disease (AD) is one of the most important neurodegenerative disorders, bringing about huge medical and social burden in the elderly worldwide. Many aspects of its pathogenesis have remained unclear and no effective treatment exists for it. Within the past 20 years, various mice models harboring AD-related human mutations have been produced. These models imitate diverse AD-related pathologies and have been used for basic and therapeutic investigations in AD. In this regard, there are a wide variety of preclinical trials of potential therapeutic modalities using AD mice models which are of paramount importance for future clinical trials and applications. This review summarizes more than 140 substances and treatment modalities being used in transgenic AD mice models from 2001 to 2011. We also discuss advantages and disadvantages of each model to be used in therapeutic development for AD.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1568163712001389; http://dx.doi.org/10.1016/j.arr.2012.09.002; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84867366916&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22982398; https://linkinghub.elsevier.com/retrieve/pii/S1568163712001389; https://dx.doi.org/10.1016/j.arr.2012.09.002
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know